## ANALYSIS OF OPTIC NERVE HEAD PARAMETERS, RETINAL NERVE FIBER LAYERS AND MACULAR THICKNESS IN HELICOBACTER PYLORI INFECTION PATIENTS

### DR AHMAD KAMAL GHANIMI BIN ZAMLI

## DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF MEDICINE

### (OPHTHALMOLOGY)



### **UNIVERSITI SAINS MALAYSIA**

2019

#### DISCLAIMER

I hereby certify that the work in this my own except for the quotations and summaries which have been duly acknowledged.

Date: 27<sup>th</sup> May 2019

Dr. Ahmad Kamal Ghanimi Bin Zamli

PUM 0133/14

#### ACKNOWLEDGMENT

Alhamdulillah, thank you Allah for the opportunity. May this study will be of benefits to mankind.

I would like to extend my gratitude to my supervisor, Professor Dr Wan Hazabbah Bin Wan Hitam, Consultant Ophthalmologist (neuro-ophthalmological), Department of Ophthalmology, School of Medical Sciences, Universiti Sains Malaysia for his expert guidance and continuous encouragement. I have the opportunity to learn a lot from a great figure.

Special thanks to my Co-supervisors Professor Dr Lee Yeong Yeh and Dr Nazri Mustaffa from the Department of Internal Medicine, School of Medical Sciences, Universiti Sains Malaysia for the invaluable input regarding *Helicobacter pylori*. Also, a special thanks to Dr Norasiah Abu Bakar from Hospital Raja Perempuan Zainab II for contributing inputs and suggestions during the preparation of the protocol.

I would also like to express my sincerest gratitude for the help extended to me by my colleagues and staffs of Ophthalmology Department and Endoscopic Department, Universiti Sains Malaysia for the help and support given. Without their help, this study would not come to materialized.

Special thanks to Dr Siti Azrin bt Abd Hamid, statistician from Department of biostatistics and research methodology, USM for her invaluable advice and help throughout the process of identifying statistical problem. I would also thanks my dearest friends Dr Tan Chew Ean and Dr Siti Amirah Hassan, for the help in collecting data and giving suggestions for the study. With your help and encouragement, this study has come into its final.

Last but not least, I would like to thank all my family members for their continuous support, prayers, encouragement and sacrifices that they made for me to be in this journey. All of you are my pillars and motivators. Thank you.

#### **TABLE OF CONTENTS**

TITLE	i	
DISCLAIMER		
ACKNOWLEDGEMENT TABLE OF CONTENTS		
ABSTRACT (ENGLISH)		
CHAPTER 1: INTRODUTION		
1.1 Helicobacter pylori	2	
1.1.1 Virulence Factors	2	
1.1.1.1 CagA	2	
1.1.1.2 VacA	3	
1.2 Epidemiology of Helicobacter pylori Infection	3	
1.3 Extragastric Manifestation of Helicobacter pylori Infection	4	
1.4 Ocular Manifestation of Helicobacter pylori Infection	5	
1.4.1 Glaucoma	6	
1.4.2 Central Serous Chorioretinopathy	8	
1.5 Rationale of the Study	10	
1.6 References	13	

#### **CHAPTER 2: OBJECTIVES**

2.1	General Objective	21
2.2	Specific Objectives	21

Page

#### **CHAPTER 3: MANUSCRIPT**

3.1	Abstract	25
3.2	Introduction	27
3.3	Methodology	29
3.4	Results	31
3.5	Discussion	38
3.6	Conclusion	43
3.7	Declarations	44
3.8	References	46
3.9	Submission Guidelines	51

#### **CHAPTER 4: STUDY PROTOCOL**

4.1 Introduction	70
4.2 Rationale of Study	74
4.3 Research Objectives	76
4.3.1 Research Questions	76
4.3.2 Research Hypothesis	76
4.3.3 General Objective	76
4.3.4 Specific Objectives	76
4.4 Methodology	77
4.4.1 Study Design	77
4.4.2 Study Location	77
4.4.3 Selection Criteria	78
4.4.4 Sample Size	79
4.4.5 Sample Size Calculations	80
4.4.6 Sampling Method	83
4.5 Definition of Terms	83
4.6 Research Tools	85
4.7 Data Collection Procedures	86
4.8 Methods to Minimize Errors	87
4.9 Flow Chart	88
4.10 Statistical Analysis	89
4.11 Ethical Considerations	93
4.12 Declaration of Conflict of Interest	93
4.13 Budget	93

4.14 Gantt Chart	94
4.15 References	95

#### **CHAPTER 5: APPENDICES**

Appendix A: Ethical Approval Form	99
Appendix A. Euncal Appioval Politi	77

#### ABSTRAK (BAHASA MALAYSIA)

#### Latar Belakang

*Helicobacter pylori (H. pylori)* telah diketahui mempunyai manifestasi extragastric. Bahagian mata juga tidak terlepas daripada menunjukkan perkaitan diantara *H. pylori* dengan glaukoma sudut terbuka dan "*chorioretinopathy serous*". Kedua-dua penyakit ini boleh menimbulkan ancaman besar kepada penglihatan dan boleh menyebabkan kebutaan jika tidak dikenalpasti awal. Tujuan kajian ini adalah untuk menilai parameter saraf optik utama (ONH), ketebalan lapisan serat saraf retina (RNFL) dan ketebalan makular pada pesakit yang menghidapi jangkitan *H. pylori* dan membandingkannya dengan subjek kawalan.

#### Kaedah:

Satu kajian rentas perbandingan rawak telah dijalankan di Unit Endoskopik Hospital Universiti Sains Malaysia dari Mac 2017 sehingga Jun 2018. Parameter – parameter ONH, RNFL dan ketebalan makular telah diambil menggunakan Pemeriksaan OCT SD-Cirrus. Analisis statistik dilakukan menggunakan Pakej Statistik untuk Sains Sosial, Versi 24.

#### Keputusan:

Seramai 80 pesakit direkrut ke dalam kajian ini. Empat puluh orang calon dengan jangkitan *H. pylori* dikelompokkan di bawah kelompok positif *H. pylori* manakala 40 orang dewasa yang sihat dikelompokkan di bawah subjek kawalan. Umur minima bagi pesakit positif *H. pylori* adalah 52.43  $\pm$ 15.67 tahun. Ketebalan RNFL adalah tidak simetri di kumpulan *H. pylori* 81.73%  $\pm$  12.81 (p = 0.015). Tiada perbezaan ketara yang dilihat terhadap lain – lain parameter ONH dan RNFL. Terdapat juga peningkatan parameter ketebalan makular di

bahagian "inferior inner", "nasal inner" dan "nasal outer" selepas faktor umur dan jantina diambil kira.

#### Kesimpulan:

Kajian ini menunjukan ketebalan RNFL di kumpulan *H. pylori* adalah tidak simetri dan ini boleh memberi petunjuk terhadap tanda awal kecederaan saraf optik utama. Terdapat juga kenaikan purata ketebalan makular di beberapa kawasan retina pada pesakit yang dijangkiti bakteria *H. pylori*.

#### Kata kunci:

Helicobacter pylori, ONH, RNFL, ketebalan Macular

#### **ABSTRACT (ENGLISH)**

#### Background

*Helicobacter pylori* (*H. pylori*) has been known to have extra-gastric manifestations. The eye was not spared as in recent years studies have shown the association of *H. pylori* with glaucoma and central serous chorioretinopathy (CSCR). Both diseases posed a significant threat to the vision and can lead to blindness if untreated. This study aimed to evaluate the optic nerve head (ONH) parameters, retinal nerve fibre layers (RNFL) and macular thickness in patients with *Helicobacter pylori* infection and comparing it with controls.

#### **Methods:**

A randomised comparative cross-sectional study was conducted at Endoscopic Unit. of Hospital Universiti Sains Malaysia from March 2017 to June 2018. The ONH parameters, RNFL and macular thickness was taken using SD-Cirrus OCT examinations. Statistical analysis was done using Statistical Package for the Social Science, Version 24.

#### **Results:**

A total of 80 patients were included in this study. Forty candidates with *H. pylori* infection were grouped under *H. pylori* positive group while another 40 healthy adults were grouped under controls. The mean age for *H. pylori* positive patients were  $52.43 \pm 15.67$  years old. There were asymmetrical RNFL thickness in *H. pylori* group,  $81.73\% \pm 12.81$  (p = 0.015). No significant differences were observed on other ONH and RNFL parameters. Macula thickness parameters showed an increase in thickness at the *inferior* inner, nasal inner and nasal outer quadrant after controlling for age and gender.

#### **Conclusion:**

This study showed that there is asymmetrical RNFL thickness in *H. pylori* patients and may suggest the possibility of optic nerve damage. There was also an increase in several areas of retinal thickening in patients with *H. pylori* infection patients.

#### **Keywords:**

Helicobacter pylori, ONH, RNFL, Macular thickness.

# CHAPTER 1

# BACKGROUND

#### **1.1 Helicobacter Pylori**

*Helicobacter pylori (H. pylori)* is a gram-negative, spiral-shaped bacterium which is most commonly found in gastric mucosa. Eventhough Bottcher had first discovered an unknown bacterium that caused gastric ulcer in 1875, it was Warren and Marshal that had first cultured this bacterium and described it as a Campylobacter like bacterium (Bottcher, 1874; Warren and Marshall, 1983). This finding had led Warren and Marshal to receive a Nobel Prize in Medicine in 2005 for the discovery of *H. pylori* infection and its role in gastritis and peptic ulcer diseases. Further studies by Nomura et al. have found an association between gastric cancer and *H. pylori* infection (Nomura et al., 1991). Since then, the study of *H. pylori* has been enormous which subsequently leads to the discovery of multiple strains and virulence factors which spreads extensively across the world.

#### **1.1.1 Virulence Factors**

The pathogenicity of *H. pylori* was not contributed by only a single virulence factor but occurred in multifactorial. The effect of vacuolisation, carcinogenicity, formation of reactive oxygen species (ROS) and the ability to induce cell death by apoptosis, were the complications of *H. pylori* infection (Izzotti et al., 2009; Testerman and Morris, 2014).

#### 1.1.1.1 Cytotoxin Associated Gene A

The most important virulence factor is cytotoxin associated gene A (CagA) which is responsible for the cell carcinogenesis and also formation of hydrogen peroxide (Butcher et al., 2017). *H. pylori* bacterium will directly inject CagA protein into the host cell cytoplasm and this will affect the host cell physiology as well as changing the cytoskeleton structure of the gastric epithelium (Higashi et al., 2002; Kao et al., 2016). These changes

can induce the release of tumor necrosis  $\alpha$  (TNF- $\alpha$ ) and interleukin 8 (IL-8), which are the inflammatory mediators, and promoting the migration of polymorphonuclear cell (PMN). Subsequently, PMN will release hydrogen peroxide (a component of ROS) to kill the bacterium (El Miedany et al., 2005). However due to the location of the bacterium itself which is located within the lumen of the gastric mucosa, elimination of *H. pylori* is difficult, and this will lead to chronic inflammation and prolonged infection (Butcher et al., 2017).

#### 1.1.1.2 Vacuolating Toxin A

Vacuolating toxin A (VacA) is responsible for inducing cell death by apoptosis. VacA has the ability to produce vacuoles within the host cells and disrupt the membrane cell wall. VacA is also capable of inserting itself through mitochondria membranes and inducing mitochondrial dysfunction which resulting in cell death (Testerman and Morris, 2014).

#### **1.2 Epidemiology of Helicobacter Pylori Infection**

Epidemiologically, the prevalence of *H. pylori* infection varies among different populations worldwide with the highest observed incidence observed in Central/South America and Asia. It is also believed that that the prevalence of *H. pylori* infection among Asian population is often higher than 50% with the elderly and low socio-economic population was the most affected group (Eusebi et al., 2014).

Malaysian population, however, have different prevalence rate among its various multiracial communities. It is found that Chinese and Indian population have a higher percentage of *H. pylori* infection if compared to Malay ethnic group (Sasidharan et al.,

2011). Another interesting study that was done in northern peninsular of Malaysia among blood donors indicates that the prevalence of *H. pylori* is very low among Malay ethnic group which is around 4.2% (Uyub et al., 1994). It is believed that the different cultural background contributed to the difference in prevalence rate among ethnicity in Malaysia, environmental factors as well as dietary factors (Lee et al., 2012).

#### **1.3 Extragastric Manifestation of Helicobacter Pylori Infection**

The two main diseases in which *H. pylori* is commonly associated with are gastritis and peptic ulcer disease. In recent year, studies have shown that *H. pylori* also have multiple extragastric manifestations which have been described in various sites of *H. pylori* infection in human (Testerman and Morris, 2014).

Within the gastrointestinal tract, amongst the sites that were found to harbour *H. pylori* infection other than the stomach were the liver, gallbladder and the colon. *H. pylori* was seen to induce carcinogenesis in liver and colon which evidenced by the findings of *H. pylori* through histology and culture in hepatocellular cancer and colorectal adenocarcinoma (Hong et al., 2012; Tian et al., 2008). Within the gallbladder, in chronic cholelythiasis patients, *H. pylori* was also found to induce adenomyomatosis and metaplasia of the gallbladder mucosal layer (Zhou et al., 2013).

Furthermore, the effect of *H. pylori* infection has also been seen in skin diseases. In a study by Federman et al. that examined patients that have chronic idiopathic urticaria, *H. pylori* was found in 30.9% of the total patients affected (Federman et al., 2003). Furthermore, in another study, almost 63.6% of patients with chronic idiopathic urticaria has been in complete remission after eradication of *H. pylori* treatment given (Campanati et al., 2013).

The effect of *H. pylori* towards skin can also be seen in patients with acne rosacea. In a study by Argenziano et al. in patients with rosacea, almost 81% of their patients have harboured *H. pylori* infection (Argenziano et al., 2003). This study has been supported by El-Khalawany et al. in which they observed improvement of rosacea if patient underwent *H. pylori* eradication treatment (El-Khalawany et al., 2012).

The *H. pylori* infection was also studied in relations to neurodegenerative diseases such as in Alzheimer diseases. A study by Kountouras et al. has found that improvement in cognitive function in Alzheimer diseases has been seen in patients that underwent *H. pylori* eradication therapy (Kountouras et al., 2009). Other study that supported such finding has found a strong association of *H. pylori* seropositive with poorer cognitive functions amongst the elderly (Beydoun et al., 2013).

Further study of the effect of *H. pylori* infection towards the lungs has also come into shed when Tsang et al. has found an association of bronchiectasis with *H. pylori* infection. He has found that almost 76% of patients with bronchiectasis has a seropositive for *H. pylori* infection if compared to control (Tsang et al., 1998). In fact, in patients with chronic obstructive pulmonary diseases (COPD), a study have found that COPD patients have higher seroprevalence if compared to controls (Prónai et al., 2004).

#### **1.4 Ocular Manifestation of Helicobacter Pylori Infection**

*H. pylori* was also believed to cause several diseases of the ocular. There were few studies that have shown the role of *H. pylori* in affecting the eyelid and causing anterior blepharitis. Saccà et al. has found that patients with blepharitis were more common to have superimposed *H. pylori* infection if compared to controls (30.6% vs 13.4%). Furthermore,

between the control and *H. pylori* infection, blepharitis in seropositive *H. pylori* was seen to be more severe but responded well to eradication treatment (Saccà et al., 2006). Even though the team was quite sceptical in defining the association of blepharitis and *H. pylori*, the data had suggested that *H. pylori* might play a role in the severity of the diseases itself.

Another structure of the eye that can be affected by *H. pylori* is the uveal tissue. Anterior uveitis, which is a term to describe the inflammation of the anterior aspect of the uveal tissue, was found to also caused by *H. pylori*. A study by Otasevic et al. has found the role of *H. pylori* in causing not only acute anterior uveitis, but also chronic spondyloarthropaties. In their study, seropositive *H. pylori* was seen higher in patients with acute anterior uveitis (at least 66.7% of patients in anterior uveitis) if compared to controls (26.7%) (Otasevic et al., 2006)

Other two most studied diseases of the ocular in *H. pylori* are glaucoma and CSCR. Below are the pathogenesis of *H. pylori* in both of the diseases.

#### 1.4.1 Glaucoma

The role of *H. pylori* in the pathogenesis of primary open angle glaucoma (POAG) has been proposed by Kountouras et al. and Izotti et al. in which both of the teams explained regarding the role of ROS that can induce chronic oxidative stress towards the trabecular meshwork (TM) (Izzotti et al., 2009; Kountouras et al., 2011). These chronic systemic oxidative stress secondary to the continuous release of ROS by PMN will induce the expression of inflammatory mediators and oxidative tissue damage to the TM. This condition will result in the changes of the extracellular matrix and cytoskeleton of the TM cell and also inducing cell decay (Babizhayev, 2016). Subsequently, the aqueous outflow will be affected and resulting in increasing intraocular pressure.

Other proposed pathogenesis of the role of *H. pylori* is by the direct invasion of the bacterium itself towards the TM that can caused subclinical inflammation and subsequently inducing cross mimicry between endothelium and *H. pylori* antigen. This was evidenced by the findings of Zavos and Kountouras that have shown a direct invasion of *H. pylori* into the TM (Zavos and Kountouras, 2012). They reported the existence of *H. pylori* through iris and TM tissue cultures in POAG patient that underwent trabeculectomy. This evidence has further shed light in the role of *H. pylori* in glaucoma.

Furthermore, *H. pylori* infection was not only affecting the TM, but it is also capable to induce retinal ganglion cell death through apoptosis and leading to glaucomatous changes. In glaucomatous optic neuropathy, high oxidative stress is a known factor in pathogenesis of glaucoma changes (Chrysostomou et al., 2013; Saccà et al., 2007). Among patients with *H. pylori* infection, high levels of ROS and circulating peroxides were believed to be an important apoptotic signals that can leads to glaucoma (Izzotti et al., 2009). These oxidative stress (ROS and peroxides) were believed to induced mitogen-activated protein kinase (MAPK), TNF-α and interferon gamma which are precursor for apoptotic process that can leads to optic nerve head (ONH) degeneration (Izzotti et al., 2009; Winter-Vann and Johnson, 2007). Furthermore, ROS also able to induce extracellular glutamate within the ganglion cells and inducing excitotoxicity leading to cell death (Epstein et al., 1994). All of these pathogenesis proposed by the studies may leads to ONH and retinal nerve fibre layer (RNFL) damage.

#### **1.4.2 Central Serous Chorioretinopathy**

Central serous chorioretinopathy is a diseases characterized by a serous detachment of the neurosensory retina in the macula area (Giusti, 2004; Mateo-Montoya and Mauget-Faÿse, 2014). Patients with CSCR may presented with blurring of vision, positive scotoma, micropsia, metamorphosia and impaired colour vision due to the alteration of the macula anatomical configuration by fluid accumulation (Giusti, 2004). Even though CSCR has a favourable outcome in most of the patients, in a small percentage of the patients, CSCR can be persistent and resulted in permanent visual loss. There were no effective treatment available for the patients and this is due to the lack of precise knowledge of its pathogenesis and causative factors.

Evidence of the role of *H. pylori* in developing CSCR was first described by Giusti in his case report. He have found that the recurrence of CSCR in a 43 years old gentleman were associated with the seropositive of *H. pylori* infection. He also observed that the thickness of the macula area showed significant improvement after the successful eradication of *H. pylori* infection (Giusti, 2004). For this reason, a prospective study of 16 patients with CSCR has been done by Mauget et al to search for the causative link of *H. pylori* and CSCR. Interestingly, the study showed a significantly higher prevalence of *H. pylori* was detected in patients with CSCR (Mauget-Faÿsse et al., 2002). A similar findings has been found by Asensio et al which found that seropositive of *H. pylori* was higher in CSCR patients if compared to controls (Asensio-Sánchez et al., 2008).

The proposed pathogenesis for *H. pylori* in developing CSCR has been described by multiple authors with the basic principle of choriocapilaries damage and accumulation of subretinal fluid in the macula area. Cotticelli et al. proposed that *H. pylori* itself will lead to sustained release of cytokines and vasoactives that can alter the endothelial cells of choriocapilaries under the macula (Cotticelli et al., 2006). Other pathogenesis of CSCR suggested by Franceschi et al. discusses about the role of anti-CagA antibodies interaction with the host (Franceschi et al., 2002). In this case, anti-CagA antibodies possessed a cross mimicry with the vascular wall antigens which then can lead to endothelial dysfunction and leakage. Further microangiopathy and occlusion within the choroidal microcirculation will lead to the decompensation of retinal pigment epithelium and subsequently progression towards developing CSCR (Giusti, 2004).

#### 1.5 Rationale of the Study

This study was intended to search for the association of *H. pylori* infection in developing extra gastric manifestation, particularly in the ONH, RNFL and macula. Furthermore, since almost half of Asian populations were estimated to have *H. pylori* infection, it is imperative for us to determine the effects of *H. pylori* in developing glaucoma or CSCR (Eusebi et al., 2014).

While glaucoma is the second leading cause of blindness in the world, its aetiology is still unclear. Recent studies were only able to detect the risk factors for developing glaucoma. The most common modifiable risk factor for glaucoma is elevated intraocular pressure (IOP) (Distelhorst and Hughes, 2003). However, even with the control of IOP to a specific target, the progression of ONH and RNFL damage still continue and thus jeopardizing the patients' vision. Recent evidences have shown that RNFL changes in glaucoma were caused not only by a single factor, but occurred in multifactorial. Such factors that are known to cause RNFL damage are impaired ocular blood flow, oxidative stress, cytokines and autoimmune mechanism (Chrysostomou et al., 2013; Hohenstein-Blaul et al., 2016; Kokubun et al., 2018; Tezel, 2006). In recent studies, such evidences has been proposed by Izzotti et al and Kountouras et al. that emphasize on the high level of oxidative stress in *H. pylori* infection, that may leads not only TM damage, but also ONH and RNFL damage (Izzotti et al., 2009; Kountouras et al., 2011).

However, both of the team had use only POAG patients which already have underlying RNFL loss to search for the complication of *H. pylori* infection. Meanwhile, the study of the effects of *H. pylori* infection towards ONH and RNFL per se in patients with no sign

and symptoms of glaucoma is scarce and was only done by Atilgan et al. in their study. Atilgan et al. has search for the possible effects of *H. pylori* infection towards the ONH and RNFL before and after treatment commencement and subsequently comparing it to healthy control. Their result had shown that the defects seen in H. pylori infected patients in the ONH and RNFL was persistent even after eradication treatment was started (Atilgan et al., 2017). This has shown as an evidence that the ONH and RNFL damage, similar to glaucoma, were permanent and irreversible. This further emphasize that the study of ONH and RNFL in patients with *H. pylori* infection may leads to timely detection of structural damage and thus can halt the progression of RNFL loss through early intervention. Moreover, since the structural damage that occur in the ONH and RNFL were believed to be affected first before functional damage of visual field defects, this study was also aimed to look for these early damages rather than functional damage (Johnson et al., 2000). In fact, Johnson et al. also emphasised on the important of detecting structural damage in the early stage of glaucoma that can be accurately related to visual field changes . A quantitative measurements by OCT in detecting structural damage means a more accurate approach can be applied in determining early ONH and RNFL damage. Therefore, due to this belief, Zullo et al. called for extensive research for its pathogenesis that should be done in order for better management of glaucoma patients (Zullo et al., 2012). At the same time, this study will also lead to a better understanding of the role of *H. pylori* in glaucomatous optic nerve damage.

On the other hand, the effects of *H. pylori* towards the macula has only been studied in patients whom already had macula thickening. The detection of high seroprevalence of *H. pylori* in CSCR may indicate that a causal link is possible between these two entities. Both of the pathogenesis proposed regarding the role of *H. pylori* in CSCR has emphasized the

effects of *H. pylori* in causing vascular endothelial damage, which can subsequently leads to macula thickening and visual disturbances. Such damage is evidenced by the disruption of the choroidal and choriocapillaries circulation in CSCR patients with *H. pylori* infection. Furthermore, focal occlusion of choroidal microcirculation in CSCR evidenced by non-profuse areas, filling delays of the choroidal and choriocapillaries, as well as reduced blood flow during fluorescein and indocyanin green angiography had further strengthened the proposed pathogenesis of CSCR in *H. pylori* infection (Horozoglu et al., 2018). Even though CSCR is known to resolve by itself, almost 50% of the patients may develop recurrence (Giusti, 2004). Early detection of macula thickening in patients with *H. pylori* infection may leads to a better prognosis by preventing recurrence as found by Giusti in his case report (Giusti, 2004).

Thus, with rising evidences of relationship of RNFL and ONH damage with *H. pylori* infection which was described by Kountouras et al. and few other similar studies in different populations, as well as relationship of macula thickening in CSCR with *H. pylori* as described by Giusti, the need for thorough evaluation of *H. pylori* role in the eye diseases, mandate an analysis study to be done (Giusti, 2004; Kountouras et al., 2017).

#### **1.6 References**

Argenziano, G., Donnarumma, G., Iovene, M. R., Arnese, P., Baldassarre, M. A., & Baroni, A. (2003). Incidence of anti-*Helicobacter pylori* and anti-CagA antibodies in rosacea patients. *International Journal of Dermatology*, **42**(8), 601–604. doi:10.1046/j.1365-4362.2003.01817.x

Asensio-Sánchez, V. M., Rodríguez-Delgado, B., García-Herrero, E., Cabo-Vaquera, V., & García-Loygorri, C. (2008). Central serous chorioretinopathy as an extradigestive manifestation of *Helicobacter pylori* gastric infection. *Archivos de La Sociedad Espanola de* 

*Oftalmologia*, **83**(**3**), 177–82.

Atilgan, C. U., Kosekahya, P., Yozgat, A., Sen, E., Berker, N., Caglayan, M., ... Yilmazbas, P. (2017). Are optic nerve heads of patients with *Helicobacter pylori* infection more susceptible to glaucomatous damage? *Helicobacter*, **22**(**6**), e12443. doi:10.1111/hel.12443

Babizhayev, M. A. (2016). Generation of reactive oxygen species in the anterior eye segment. Synergistic codrugs of N-acetylcarnosine lubricant eye drops and mitochondria-targeted antioxidant act as a powerful therapeutic platform for the treatment of cataracts and primary open-an. *BBA Clinical*. doi:10.1016/j.bbacli.2016.04.004

Beydoun, M. A., Beydoun, H. A., Shroff, M. R., Kitner-Triolo, M. H., & Zonderman, A.
B. (2013). *Helicobacter pylori* seropositivity and cognitive performance among US adults: evidence from a large national survey. *Psychosomatic Medicine*, **75**(5), 486–96. doi:10.1097/PSY.0b013e31829108c3

Bottcher A. (1874). Zur Genese des perforirenden Magengeschwurs. *Dorpater Medicinische Zeitschrift*, **5**, 148–151. Retrieved from http://ci.nii.ac.jp/naid/10015424476/en/

13

Butcher, L. D., den Hartog, G., Ernst, P. B., & Crowe, S. E. (2017, May). Oxidative Stress Resulting From *Helicobacter pylori* Infection Contributes to Gastric Carcinogenesis. *CMGH*. doi:10.1016/j.jcmgh.2017.02.002

Campanati, A., Gesuita, R., Giannoni, M., Piraccini, F., Sandroni, L., Martina, E., ... Offidani, A. (2013). Role of Small Intestinal Bacterial Overgrowth and *Helicobacter pylori* Infection in Chronic Spontaneous Urticaria: A Prospective Analysis. *Acta Dermato Venereologica*, **93**(**2**), 161–164. doi:10.2340/00015555-1373

Chrysostomou, V., Rezania, F., Trounce, I. A., & Crowston, J. G. (2013). Oxidative stress and mitochondrial dysfunction in glaucoma. *Current Opinion in Pharmacology*, **13**(1), 12–15. doi:10.1016/J.COPH.2012.09.008

Cotticelli, L., Borrelli, M., D'Alessio, A. C., Menzione, M., Villani, A., Piccolo, G., ... Romano, M. (2006). Central serous chorioretinopathy and *Helicobacter pylori. European Journal of Ophthalmology*, **16**(**2**), 274–8. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16703546

Distelhorst, J. S., & Hughes, G. M. (2003). Open-angle glaucoma. *American Family Physician*, **67(9)**, 1937–44. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12751655

El-Khalawany, M., Mahmoud, A., Mosbeh, A. S., Abd Alsalam, F., Ghonaim, N., & Abou-

Bakr, A. (2012). Role of *Helicobacter pylori* in common rosacea subtypes: A genotypic comparative study of Egyptian patients. *Journal of Dermatology*, **39**(**12**), 989–995. doi:10.1111/j.1346-8138.2012.01675.x

El Miedany, Y. M., Baddour, M., Ahmed, I., & Fahmy, H. (2005). Sjogren's syndrome: Concomitant *H. pylori* infection and possible correlation with clinical parameters. *Joint Bone Spine*. doi:10.1016/j.jbspin.2004.04.005 Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994). Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders. *New England Journal of Medicine*, **330(9)**, 613–622. doi:10.1056/NEJM199403033300907

Eusebi, L. H., Zagari, R. M., & Bazzoli, F. (2014). Epidemiology of *Helicobacter pylori* Infection. *Helicobacter*, **19**, 1–5. doi:10.1111/hel.12165

Federman, D. G., Kirsner, R. S., Moriarty, J. P., & Concato, J. (2003). The effect of antibiotic therapy for patients infected with *Helicobacter pylori* who have chronic urticaria. *Journal of the American Academy of Dermatology*, **49**(5), 861–864. doi:10.1016/S0190-9622(03)00846-6

Franceschi, F., Sepulveda, A. R., Gasbarrini, A., Pola, P., Silveri, N. G., Gasbarrini, G., ... Genta, R. M. (2002). Cross-reactivity of anti-CagA antibodies with vascular wall antigens: Possible pathogenic link between *Helicobacter pylori* infection and atherosclerosis. *Circulation*, **106**(**4**), 430–434. doi:10.1161/01.CIR.0000024100.90140.19

Giusti, C. (2004). Association of *Helicobacter pylori* with central serous chorioretinopathy: Hypotheses regarding pathogenesis. *Medical Hypotheses*, **63**(**3**), 524–527. doi:10.1016/j.mehy.2004.02.020

Higashi, H., Tsutsumi, R., Muto, S., Sugiyama, T., Azuma, T., Asaka, M., & Hatakeyama, M. (2002). SHP-2 tyrosine phosphatase as an intracellular target of *Helicobacter pylori* CagA protein. *Science*, **295**(**5555**), 683–686. doi:10.1126/science.1067147

Hohenstein-Blaul, N. V. T. U., Bell, K., Pfeiffer, N., & Grus, F. H. (2016). Autoimmune aspects in glaucoma. *European Journal of Pharmacology*, **787**, 105–118.

Hong, S. N., Lee, S. M., Kim, J. H., Lee, T. Y., Kim, J. H., Choe, W. H., ... Shim, C. S. (2012). *Helicobacter pylori* Infection Increases the Risk of Colorectal Adenomas: Cross-Sectional Study and Meta-Analysis. *Digestive Diseases and Sciences*, **57**(**8**), 2184–2194. doi:10.1007/s10620-012-2245-x

Horozoglu, F., Sever, O., Celik, E., Mete, R., & Sahin, E. (2018). Choroidal Thickness of Helicobacter-Positive Patients without Central Serous Chorioretinopathy. *Current Eye Research*, **43**(**2**), 262–265. doi:10.1080/02713683.2017.1397176

Izzotti, A., Saccà, S. C., Bagnis, A., & Recupero, S. M. (2009). Glaucoma and *Helicobacter pylori* infection: Correlations and controversies. *British Journal of Ophthalmology*. doi:10.1136/bjo.2008.150409

Johnson, C. A., Cioffi, G. A., Liebmann, J. R., Sample, P. A., Zangwill, L. M., & Weinreb, R. N. (2000). The Relationship Between Structural and Functional Alterations in Glaucoma: A Review. *Seminars in Ophthalmology*, **15**(**4**), 221–233. doi:10.3109/08820530009037873

Kao, C. Y., Sheu, B. S., & Wu, J. J. (2016). *Helicobacter pylori* infection: An overview of bacterial virulence factors and pathogenesis. *Biomedical Journal*. doi:10.1016/j.bj.2015.06.002

Kokubun, T., Tsuda, S., Kunikata, H., Yasuda, M., Himori, N., Kunimatsu-Sanuki, S., ... Nakazawa, T. (2018). Characteristic Profiles of Inflammatory Cytokines in the Aqueous Humor of Glaucomatous Eyes. *Ocular Immunology and Inflammation*, **26**(**8**), 1177–1188. doi:10.1080/09273948.2017.1327605

Kountouras, J., Boziki, M., Gavalas, E., Zavos, C., Grigoriadis, N., Deretzi, G., ... Venizelos, I. (2009). Eradication of *Helicobacter pylori* may be beneficial in the management of Alzheimer's disease. *Journal of Neurology*, **256**(5), 758–767. doi:10.1007/s00415-009-5011-z

Kountouras, J., Boziki, M., Polyzos, S. A., Katsinelos, P., Gavalas, E., Zeglinas, C., ... Deretzi, G. (2017). Impact of reactive oxygen species generation on *Helicobacter pylori*related extragastric diseases: a hypothesis. doi:10.1080/10715762.2016.1271122

Kountouras, J., Zavos, C., Deretzi, G., Polyzos, S. A., Gavalas, E., Tsiaousi, E., ... Tsarouchas, G. (2011). Neuroprotection in glaucoma: Is there a future role of *Helicobacter pylori* eradication? *Experimental Eye Research*, **92**(5), 436–438. Lee, Y. Y., Ismail, A. W., Mustaffa, N., Musa, K. I., Majid, N. A., Choo, K. E., ... Graham, D. Y. (2012). Sociocultural and Dietary Practices Among Malay Subjects in the North-Eastern Region of Peninsular Malaysia: A Region of Low Prevalence of *Helicobacter pylori* Infection. *Helicobacter*, **17**(1), 54–61. doi:10.1111/j.1523-5378.2011.00917.x

Mateo-Montoya, A., & Mauget-Faÿse, M. (2014). *Helicobacter pylori* as a risk factor for central serous chorioretinopathy: Literature review. *World Journal of Gastrointestinal Pathophysiology*, **5**(**3**), 355–8. doi:10.4291/wjgp.v5.i3.355

Mauget-Faÿsse, M., Kodjikian, L., Quaranta, M., Ben Ezra, D., Trepsat, C., Mion, F., & Mégraud, F. (2002). [*Helicobacter pylori* in central serous chorioretinopathy and diffuse retinal epitheliopathy. Results of the first prospective pilot study]. *Journal Francais d'ophtalmologie*, **25**(**10**), 1021–5.

Nomura, A., Stemmermann, G. N., Chyou, P.-H., Kato, I., Perez-Perez, G. I., & Blaser, M. J. (1991). *Helicobacter pylori* Infection and Gastric Carcinoma among Japanese Americans in Hawaii. *New England Journal of Medicine*, **325**(**16**), 1132–1136. doi:10.1056/NEJM199110173251604

Otasevic, L., Zlatanovic, G., Stanojevic-Paovic, A., Miljkovic-Selimovic, B., Dinic, M., Djordjevic-Jocic, J., & Stankovic, A. (2006). *Helicobacter pylori*: An underestimated factor in acute anterior uveitis and spondyloarthropathies? *Ophthalmologica*, **221**(1), 6–13. doi:10.1159/000096515

Prónai, L., Schandl, L., Orosz, Z., Magyar, P., & Tulassay, Z. (2004). Lower prevalence of *Helicobacter pylori* infection in patients with inflammatory bowel disease but not with chronic obstructive pulmonary disease - Antibiotic use in the history does not play a significant role. *Helicobacter*, **9**(**3**), 278–283. doi:10.1111/j.1083-4389.2004.00223.x

Robin Warren, J., & Marshall, B. (1983). Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *The Lancet*. doi:10.1016/S0140-6736(83)92719-8

Saccà, S. C., Izzotti, A., Rossi, P., & Traverso, C. (2007). Glaucomatous outflow pathway and oxidative stress. *Experimental Eye Research*, **84**(**3**), 389–399. doi:10.1016/J.EXER.2006.10.008

Saccà, S. C., Pascotto, A., Venturino, G. M., Prigione, G., Mastromarino, A., Baldi, F., ... Rebora, A. (2006). Prevalence and treatment of *Helicobacter pylori* in patients with blepharitis. *Investigative Ophthalmology and Visual Science*, **47**(**2**), 501–508. doi:10.1167/iovs.05-0323

Sasidharan, S., Lachumy, S. J. T., Ravichandran, M., Latha, L. Y., & Gegu, S. R. S. (2011). Epidemiology of *Helicobacter pylori* among multiracial community in Northern Peninsular, Malaysia: effect of age across race and gender. *Asian Pacific Journal of Tropical Medicine*, **4**(1), 72–75. doi:10.1016/S1995-7645(11)60037-0

Testerman, T. L., & Morris, J. (2014). Beyond the stomach: An updated view of *Helicobacter pylori* pathogenesis, diagnosis, and treatment. *World Journal of Gastroenterology*. doi:10.3748/wjg.v20.i36.12781

Tezel, G. (2006). Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. *Progress in Retinal and Eye Research*, **25**(**5**), 490–513. doi:10.1016/j.preteyeres.2006.07.003

Tian, X. F., Fan, X. G., Zhang, Y., Huang, Y., Dai, H., & Ying, R. S. (2008). Procuration and identification of bacteria in paraffin-embedded liver tissues of hepatocellular carcinoma by laser-assisted microdissection technique. *Apmis*, **116**(**1**), 10–15. doi:10.1111/j.1600-0463.2008.00739.x

Tsang, K. W., Lam, S. K., Lam, W. K., Karlberg, J., Wong, B. C., Hu, W. H., ... Ip, M. S. (1998). High seroprevalence of *Helicobacter pylori* in active bronchiectasis. *American Journal of Respiratory and Critical Care Medicine*, **158**(**4**), 1047–1051. doi:10.1164/ajrccm.158.4.9712104

18

Uyub, A. M., Raj, S. M., Visvanathan, R., Nazim, M., Aiyar, S., Anuar, A. K., & Mansur, M. (1994). *Helicobacter pylori* Infection in North-Eastern Peninsular Malaysia Evidence for an Unusually Low Prevalence. *Scandinavian Journal of Gastroenterology*, **29**(**3**), 209–213. doi:10.3109/00365529409090465

Winter-Vann, A. M., & Johnson, G. L. (2007, November 1). Integrated activation of MAP3Ks balances cell fate in response to stress. *Journal of Cellular Biochemistry*. John Wiley & Sons, Ltd. doi:10.1002/jcb.21522

Zavos, C., & Kountouras, J. (2012). Further data on the association between *Helicobacter pylori* infection and primary open-angle glaucoma. *Clinical Ophthalmology (Auckland, N.Z.)*, **6**, 243–5. doi:10.2147/OPTH.S29796

Zhou, D., Guan, W., Wang, J., Zhang, Y., Gong, W., & Quan, Z. (2013). A Comparative Study of Clinicopathological Features between Chronic Cholecystitis Patients with and without *Helicobacter pylori* Infection in Gallbladder Mucosa. *PLoS ONE*, **8**(7), e70265. doi:10.1371/journal.pone.0070265

Zullo, A., Ridola, L., Hassan, C., Bruzzese, V., Papini, F., & Vaira, D. (2012). Glaucoma and *Helicobacter pylori*: Eyes wide shut? *Digestive and Liver Disease*, **44**(**8**), 627–628. doi:10.1016/j.dld.2012.03.011

# CHAPTER 2

# **OBJECTIVES**

#### 2.0 General Objectives

To evaluate the optic nerve head parameters and macula thickness in patients with *Helicobacter pylori* infection.

#### **2.1 Specific Objectives**

#### 2.1.1

To compare the mean of optic nerve head parameters between patients with *Helicobacter pylori* infections and control.

#### 2.1.2

To compare the mean of retinal nerve fibre layer thickness between patients with *Helicobacter pylori* infections and control.

#### 2.1.3

To compare the mean of macula thickness in patients with *Helicobacter pylori* infections and control.

# CHAPTER 3

# MANUSCRIPT

## Analysis of Optic Nerve Head Parameters, Retinal Nerve Fiber Layers and Macula Thickness in Helicobacter Pylori Infection

Ahmad Kamal Ghanimi Zamli<sup>1</sup>, Wan Hazabbah WH<sup>1</sup>, Lee Yeong Yeh<sup>1</sup>, Nazri Mustaffa<sup>1</sup>, Norasiah Bt Abu Bakar<sup>2</sup>.

- Department of Ophthalmology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
- Department of Internal Medicine, Hospital Raja Perempuan Zainab II, Kota Bharu,Kelantan, Malaysia.

#### AUTHORS

1. Ahmad Kamal Ghanimi Zamli (Corresponding Author)

Dockamal83@gmail.com

Department of Ophthalmology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia,

16150 Kubang Kerian, Kelantan, Malaysia

2. Wan Hazabbah Wan Hitam

hazabbah@usm.my

Department of Ophthalmology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia,

16150 Kubang Kerian, Kelantan, Malaysia

3. Lee Yeong Yeh

#### yylee@usm.my

Department of Ophthalmology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia,

16150 Kubang Kerian, Kelantan, Malaysia

4. Nazri Mustaffa

#### mustaffa.nazri@gmail.com

Department of Ophthalmology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia,

16150 Kubang Kerian, Kelantan, Malaysia

5. Norasiah Bt Abu Bakar

drnorasiah@gmail.com

Department of Internal Medicine, Hospital Raja Perempuan Zainab II,

Kota Bharu, Kelantan, Malaysia

Conflict of interest: No conflicting relationship exists for any author.